Akoya Biosciences, Inc.

Announcing the Recipient of the IO60 Spatial Omics Grant Program We are thrilled to announce that Lorena Rosas, PhD, Research Senior Associate, and her mentors, Drs. Mauricio Rojas and Ana L. Mora, from the Department of Internal Medicine at The Ohio State University, have been awarded our IO60 Spatial Omics Grant! Their groundbreaking research will utilize the PhenoCycler®-Fusion 2.0 platform and PhenoCode IO60 panel to analyze key immune cell types, such as NK cells, within IPF lung tissue. Learn more: https://lnkd.in/d2ynPxac Congratulations, Dr. Lorena Rosas and Professors Mauricio Rojas and Ana L. Mora! We look forward to collaborating on this transformative project. Find out how PhenoCycler-Fusion and the PhenoCode IO60 Panel can transform your discoveries, https://lnkd.in/dUA52qAM

In case you missed it 🔊 Last week, we shared a revolutionary study, where Arutha Kulasinghe and colleagues at The University of Queensland have performed spatial interaction mapping in head and neck cancer patient samples, using a combination of spatial proteomics from Akoya Biosciences, Inc. and Navinci’s PD1/PD-L1 in situ proximity ligation assay. At Society for Immunotherapy of Cancer (SITC) last year, Arutha Kulasinghe presented a poster about this work – take a look at the video below to hear about the findings.   Interested to learn more about the study? Check out the full text article here: https://lnkd.in/gGiiTgjM Wesley Research Institute, University of Technology Sydney

A striking image of metastatic pancreatic cancer in the liver—surrounded by collagen and a few resilient immune cells. But what if you could classify this tumor as basal-like based on its transcriptional profile? (Pic 2) Or determine its proliferation status and pinpoint its cell cycle phase? (Pic 3) Maybe you’re curious about the immune checkpoints expressed by these infiltrating immune cells? (Pic 4) This is all part of our high-plex PDAC comprehensive panel, which includes ~60 proteins to dissect both the tumor intrinsic features and its microenvironment. A challenging task, but incredibly rewarding. Absolute pathology! Work done using Phenocycler Fusion 2.0, from Akoya, and brilliantly executed by Emma Coleman at the Wolpin-Nowak lab! #pathology #digitalpathology #pancreas #pdac

Head and neck cancer is an aggressive disease often diagnosed at advanced stages. Each year, nearly one million new cases are reported worldwide.   In a groundbreaking study, researchers from Wesley Research Institute’s Queensland Spatial Biology Centre (QSBC), along with researchers from The University of Queensland’s Frazer Institute, the Royal Brisbane and Women's Hospital and Princess Alexandra Hospital, have uncovered a crucial factor that determines whether patients with head and neck cancer will respond to immunotherapy - a finding that could pave the way for more effective treatments and improved survival rates.  Using the QSBC’s advanced imaging techniques, the research team closely examined immune interactions in tumour samples from 35 patients with head and neck cancer.  The new study has revealed that the presence of dense layers of macrophages - immune cells that typically engulf and destroy harmful invaders - may actually create a barrier that prevents immune cells from attacking the tumour. This immune blockade appears to be a key factor in why some patients fail to respond to ICI therapy.  The study’s findings suggest that future immunotherapy approaches could involve strategies to break down these immune barriers, either through new drug combinations or techniques that enhance immune cell penetration into the tumour. Additionally, the implications of this research extend beyond head and neck cancer, with potential applications for lung, bladder, colorectal and melanoma.  Read the publication - https://lnkd.in/gGiiTgjM #research #spatialmapping #spatialbiology #headandneckcancer Arutha Kulasinghe Meg Donovan, PhD Rafael Tubelleza University of Technology Sydney The University of Queensland Navinci Akoya Biosciences, Inc. Metro North Health Metro South Health

Cambridge researchers - On Wednesday 19th Feb we will be running a spatial biology seminar at the Cambridge Stem Cell Institute in collaboration with Enable Medicine. If you have been considering implementing spatial proteomics in your research or are wondering how to extract meaningful data from your images, be sure to come along! Akoya Biosciences, Inc. Aaron Mayer Adam Dickinson

Spatial Interactomics of PD-1/PD-L1 in whole tissue samples from Head and Neck Cancer patients prior to Immunotherapy #SpatialInteractomics #ProximityLigation #FrazerInstUq #SpatialProteomics #SpatialMedicine Grateful for the wonderful collaborators dotted around the world Vahid Yaghoubi Naei Rafael Tubelleza Meg Donovan, PhD Agata Wicher Sara Bodbin Majid Ebrahimi Warkiani, CINSW Fellow Brett Hughes Subham Basu Robert Stad Amélie Viratham Catherine Barnett and the funding from the Passe & Williams Foundation PA Research Foundation Publication: https://lnkd.in/gz7xiQBM Tweetorial: https://lnkd.in/gY7huQDA The University of Queensland Translational Research Institute Australia Queensland Spatial Biology Centre (QSBC) Wesley Research Institute Navinci Akoya Biosciences, Inc.

Exciting Regulatory Milestone for Akoya and Acrivon Therapeutics, Inc. We are excited to share a significant regulatory milestone for Akoya and our biopharma partner Acrivon Therapeutics. It was announced that the FDA has granted Breakthrough Device Designation (BDD) for the ACR-368 OncoSignature assay in endometrial cancer, reinforcing the potential of tissue multiplexing to bring precision oncology to patients with high unmet needs such as endometrial cancer. An Acrivon-sponsored blinded, third-party KOL market research study indicated strong interest in ACR-368’s emerging clinical profile. In the U.S., an estimated 30,000+ new cases of high-grade, recurrent endometrial cancer occur annually. ESMO 2024 data for the ACR-368 registrational intent phase 2 trial showed a 62.5% confirmed ORR (95% CI, 30.4-86.5) and statistically significant prospective patient selection using the ACR-368 OncoSignature assay (p = 0.009) in endometrial cancer. Acrivon and Akoya are partnering on ongoing clinical development and future commercial use of the ACR-368 OncoSignature assay, a multiplex immunofluorescence test developed on our PhenoImager HT platform. The BDD applies to the ACR-368 OncoSignature assay + PhenoImager HT + Akoya software for the identification of cancer patients who may benefit from ACR-368 therapy. For further context, the Breakthrough Devices Program is intended to provide patients and health care providers with timely access to medical devices by speeding up development, assessment, and review for premarket approval, 510(k) clearance, and marketing authorization. This latest designation follows the prior BDD for ACR-368 OncoSignature in ovarian cancer in November 2023 and the Fast Track Designation (FTD) for ACR-368 in platinum-resistant ovarian and endometrial cancer in May 2023, highlighting the growing recognition of this innovative approach to matching patients with the therapies most likely to benefit them. We remain committed to advancing and expanding our companion diagnostics programs and look forward to providing further updates as we progress tissue multiplexing in the clinic. #SpatialProteomics #Spatialdiagnostics #PhenoImagerHT

Press Release Announcement: Akoya Biosciences Expands Spatial Biology Portfolio We have announced our strategic product roadmap, introducing new panels for neuroscience and immuno-oncology research. PhenoCode™ Discovery IO60 Panel – Already adopted by leading researchers and CROs such as Precision For Medicine, BostonGene and Infinity Scope, providing deeper insights into immune landscapes and tumor-immune interactions. Upcoming Ultrahigh-Plex Neurobiology Panels – Human and mouse panels launching in 2025, enabling spatial insights into neurodegenerative diseases, neuroinflammation, and therapeutic development. Fully optimized for PhenoCycler®-Fusion, these new tools expand our reach into oncology, inflammatory disease, and neurobiology. Read the full announcement here: https://lnkd.in/dWss8wVE #SpatialProteomics #Neuroscience #ImmunoOncology #SpatialBiology #PhenoCyclerFusion

We’re thrilled to introduce the Phenocycler-Fusion to our core lab – a cutting-edge platform designed to push the boundaries of spatial biology and single-cell analysis. 🔬 This innovative technology enables researchers to perform high-dimensional profiling on tissue samples, revolutionizing how we study disease mechanisms, biomarkers, and therapeutic responses. Feel free to reach out to our team for more information or to schedule a demo. We're excited to see the transformative impact this technology will have on your research! Kathleen Burns Namrata Singh, PhD Maria-Anna Chrysovergi Fieda Abderazzaq 🇵🇸 Jessie Cmaylo Dana-Farber Cancer Institute Harvard Medical School #SpatialBiology #SingleCellAnalysis #PhenocyclerFusion #CoreLab #ResearchInnovation #MultiOmic Akoya Biosciences, Inc. #ScientificDiscovery Read Details below: https://lnkd.in/dG3r2Wvv

Webinar Tomorrow - Defining Tumour Heterogeneity, One-Cell-at-a-Time Don’t forget to join us for this upcoming webinar where Arutha Kulasinghe will explore groundbreaking research on the tumor microenvironment (TME) in cancer patients. Focusing on immune checkpoint inhibitor responses in lung, head and neck, and skin cancers, we’ll dive into the biological mechanisms influencing patient outcomes. What you'll learn: Insights into the TME’s role in immunotherapy response How spatial-omics approaches are transforming cancer research Key differences between responders and non-responders at the cellular level Mark your calendars – you won’t want to miss this deep dive into cutting-edge cancer immunotherapy research! Date: Wednesday, 22nd January 2025 Time: 9AM PST | 12PM EST | 5PM GMT Register: LINKEDIN https://lnkd.in/g8c5vD4K